JP2016523265A5 - - Google Patents

Info

Publication number

JP2016523265A5

JP2016523265A5 JP2016522196A JP2016522196A JP2016523265A5 JP 2016523265 A5 JP2016523265 A5 JP 2016523265A5 JP 2016522196 A JP2016522196 A JP 2016522196A JP 2016522196 A JP2016522196 A JP 2016522196A JP 2016523265 A5 JP2016523265 A5 JP 2016523265A5

Authority

JP

Japan

Prior art keywords

amino acid

seq

variable region

acid sequence

chain variable

Prior art date

2014-02-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
• 239000012634 fragment Substances 0.000 claims description 29
• 150000007523 nucleic acids Chemical class 0.000 claims description 9
• 102000039446 nucleic acids Human genes 0.000 claims description 9
• 108020004707 nucleic acids Proteins 0.000 claims description 9
• 201000010099 disease Diseases 0.000 claims 6
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
• 239000013604 expression vector Substances 0.000 claims 6
• 239000003814 drug Substances 0.000 claims 5
• 229940127121 immunoconjugate Drugs 0.000 claims 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
• 229940079593 drug Drugs 0.000 claims 4
• 239000000203 mixture Substances 0.000 claims 4
• 238000000034 method Methods 0.000 claims 2
• 208000035473 Communicable disease Diseases 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 238000003782 apoptosis assay Methods 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 230000008878 coupling Effects 0.000 claims 1
• 238000010168 coupling process Methods 0.000 claims 1
• 238000005859 coupling reaction Methods 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 230000000694 effects Effects 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 230000005522 programmed cell death Effects 0.000 claims 1
• 229940124597 therapeutic agent Drugs 0.000 claims 1
• 239000013598 vector Substances 0.000 claims 1
• 239000002299 complementary DNA Substances 0.000 description 3
• 210000004976 peripheral blood cell Anatomy 0.000 description 2
• 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
• 238000010802 RNA extraction kit Methods 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1